Evidence map›Paper›PMID 42343842›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026

[Efficacy of CD4/TGF-β bispecific antibody in a mouse model of peritoneal metastasis of malignant melanoma].

Qianli Jiang, Taosong Liu, Zizhan Wang, Shan Jiang, Haiyang Wu, Yongzhen Lin, L U Shiying, Lingxi Chen, Jiaxing Zhang, Luxia Tang and 2 more

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qianli JiangClinical Trial Center,  Nanfang Hospital, Southern Medical University, Guangzhou  510515, China.
Taosong LiuFirst School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
Zizhan WangFirst School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
Shan JiangFirst School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
Haiyang WuFirst School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
Yongzhen LinSchool of International Education, Southern Medical University, Guangzhou 510515, China.
L U ShiyingSchool of Stomatology, Southern Medical University, Guangzhou 510515, China.
Lingxi ChenGuangzhou Maishi Biotechnology Co. Ltd., Guangzhou 510660, China.
Jiaxing ZhangSchool of International Education, Southern Medical University, Guangzhou 510515, China.
Luxia TangFirst School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
Rakesh Kumar RautSchool of Stomatology, Southern Medical University, Guangzhou 510515, China.
Zhongyuan XuClinical Trial Center,  Nanfang Hospital, Southern Medical University, Guangzhou  510515, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the efficacy of CD4/TGF-β bispecific antibody in a mouse model of peritoneal metastasis of melanoma.

methodsFor drug safety testing, 20 human CD4 transgenic C57BL/6J mice were randomized into 4 groups (

resultsInjection of the antibody did not produce any significant adverse effects in the mice. In the tumor-bearing mice, the application of a magnet significantly accelerated tumor development (3.80±1.79

conclusionsThe CD4/TGF‑β bispecific antibody shows significant antitumor efficacy and good safety in the mouse model of peritoneal metastasis of melanoma.

Indexed as

Antibodies, BispecificCD4 AntigensMelanomaPeritoneal NeoplasmsTransforming Growth Factor betaAnimalsDisease Models, AnimalFemaleHumansMaleMelanoma, ExperimentalMiceMice, Inbred C57BLMice, TransgenicAntibodies, BispecificCD4 AntigensTransforming Growth Factor betabispecific antibodyimmunotherapymelanomaperitoneal metastasistumor-bearing mouse models

Identifiers

PMID42343842
PMCPMC13294726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.